Literature DB >> 26839406

Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease.

Mohamed-Bilal Fares1, Bohumil Maco1, Abid Oueslati1, Edward Rockenstein2, Natalia Ninkina3, Vladimir L Buchman3, Eliezer Masliah2, Hilal A Lashuel4.   

Abstract

Lewy bodies (LBs) are intraneuronal inclusions consisting primarily of fibrillized human α-synuclein (hα-Syn) protein, which represent the major pathological hallmark of Parkinson's disease (PD). Although doubling hα-Syn expression provokes LB pathology in humans, hα-Syn overexpression does not trigger the formation of fibrillar LB-like inclusions in mice. We hypothesized that interactions between exogenous hα-Syn and endogenous mouse synuclein homologs could be attenuating hα-Syn fibrillization in mice, and therefore, we systematically assessed hα-Syn aggregation propensity in neurons derived from α-Syn-KO, β-Syn-KO, γ-Syn-KO, and triple-KO mice lacking expression of all three synuclein homologs. Herein, we show that hα-Syn forms hyperphosphorylated (at S129) and ubiquitin-positive LB-like inclusions in primary neurons of α-Syn-KO, β-Syn-KO, and triple-KO mice, as well as in transgenic α-Syn-KO mouse brains in vivo. Importantly, correlative light and electron microscopy, immunogold labeling, and thioflavin-S binding established their fibrillar ultrastructure, and fluorescence recovery after photobleaching/photoconversion experiments showed that these inclusions grow in size and incorporate soluble proteins. We further investigated whether the presence of homologous α-Syn species would interfere with the seeding and spreading of α-Syn pathology. Our results are in line with increasing evidence demonstrating that the spreading of α-Syn pathology is most prominent when the injected preformed fibrils and host-expressed α-Syn monomers are from the same species. These findings provide insights that will help advance the development of neuronal and in vivo models for understanding mechanisms underlying hα-Syn intraneuronal fibrillization and its contribution to PD pathogenesis, and for screening pharmacologic and genetic modulators of α-Syn fibrillization in neurons.

Entities:  

Keywords:  Parkinson’s disease; aggregation; alpha-synuclein

Mesh:

Substances:

Year:  2016        PMID: 26839406      PMCID: PMC4763739          DOI: 10.1073/pnas.1512876113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  63 in total

1.  Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors.

Authors:  He-Jin Lee; Soon Young Shin; Chan Choi; Young Han Lee; Seung-Jae Lee
Journal:  J Biol Chem       Date:  2001-11-27       Impact factor: 5.157

2.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

3.  Mice lacking alpha-synuclein are resistant to mitochondrial toxins.

Authors:  Peter Klivenyi; Donald Siwek; Gabrielle Gardian; Lichuan Yang; Anatoly Starkov; Carine Cleren; Robert J Ferrante; Neil W Kowall; Asa Abeliovich; M Flint Beal
Journal:  Neurobiol Dis       Date:  2005-11-18       Impact factor: 5.996

4.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.

Authors:  W Peelaerts; L Bousset; A Van der Perren; A Moskalyuk; R Pulizzi; M Giugliano; C Van den Haute; R Melki; V Baekelandt
Journal:  Nature       Date:  2015-06-10       Impact factor: 49.962

Review 5.  Genetic animal models of Parkinson's disease.

Authors:  Ted M Dawson; Han Seok Ko; Valina L Dawson
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

6.  Trans-suppression of misfolding in an amyloid disease.

Authors:  P Hammarström; F Schneider; J W Kelly
Journal:  Science       Date:  2001-09-28       Impact factor: 47.728

7.  Suppression of IAPP fibrillation at anionic lipid membranes via IAPP-derived amyloid inhibitors and insulin.

Authors:  Daniel Sellin; Li-Mei Yan; Aphrodite Kapurniotu; Roland Winter
Journal:  Biophys Chem       Date:  2010-01-28       Impact factor: 2.352

8.  Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.

Authors:  George K Tofaris; Pablo Garcia Reitböck; Trevor Humby; Sarah L Lambourne; Mark O'Connell; Bernardino Ghetti; Helen Gossage; Piers C Emson; Lawrence S Wilkinson; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurosci       Date:  2006-04-12       Impact factor: 6.167

Review 9.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

10.  alpha-Synuclein and neuronal cell death.

Authors:  Mark R Cookson
Journal:  Mol Neurodegener       Date:  2009-02-04       Impact factor: 14.195

View more
  44 in total

1.  O-GlcNAcylation of α-Synuclein at Serine 87 Reduces Aggregation without Affecting Membrane Binding.

Authors:  Yuka E Lewis; Ana Galesic; Paul M Levine; Cesar A De Leon; Natalie Lamiri; Caroline K Brennan; Matthew R Pratt
Journal:  ACS Chem Biol       Date:  2017-02-22       Impact factor: 5.100

Review 2.  The emerging role of α-synuclein truncation in aggregation and disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

Review 3.  Reverse engineering Lewy bodies: how far have we come and how far can we go?

Authors:  Mohamed Bilal Fares; Somanath Jagannath; Hilal A Lashuel
Journal:  Nat Rev Neurosci       Date:  2021-01-11       Impact factor: 34.870

4.  Carboxy-terminal truncations of mouse α-synuclein alter aggregation and prion-like seeding.

Authors:  Zachary A Sorrentino; Yuxing Xia; Kimberly-Marie Gorion; Ethan Hass; Benoit I Giasson
Journal:  FEBS Lett       Date:  2020-01-24       Impact factor: 4.124

5.  A "Clickable" Photoconvertible Small Fluorescent Molecule as a Minimalist Probe for Tracking Individual Biomolecule Complexes.

Authors:  Joomyung V Jun; Conor M Haney; Richard J Karpowicz; Sam Giannakoulias; Virginia M-Y Lee; E James Petersson; David M Chenoweth
Journal:  J Am Chem Soc       Date:  2019-01-28       Impact factor: 15.419

6.  α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease.

Authors:  Paul M Levine; Ana Galesic; Aaron T Balana; Anne-Laure Mahul-Mellier; Mariana X Navarro; Cesar A De Leon; Hilal A Lashuel; Matthew R Pratt
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-16       Impact factor: 11.205

7.  Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.

Authors:  Mari H Savolainen; Katrina Albert; Mikko Airavaara; Timo T Myöhänen
Journal:  Exp Brain Res       Date:  2017-04-24       Impact factor: 1.972

Review 8.  Interplay between α-synuclein amyloid formation and membrane structure.

Authors:  Emma I O'Leary; Jennifer C Lee
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2018-10-02       Impact factor: 3.036

9.  Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes.

Authors:  Yaping Chu; Scott Muller; Adriana Tavares; Olivier Barret; David Alagille; John Seibyl; Gilles Tamagnan; Ken Marek; Kelvin C Luk; John Q Trojanowski; Virginia M Y Lee; Jeffrey H Kordower
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

Review 10.  New Developments in Genetic rat models of Parkinson's Disease.

Authors:  Rose B Creed; Matthew S Goldberg
Journal:  Mov Disord       Date:  2018-02-08       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.